Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 2
Submit an article Journal homepage
238
Views
6
CrossRef citations to date
0
Altmetric
Original research

Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece

George Gourzoulidisa Econcare Lp, Athens, GreeceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7239-9829View further author information
ORCID Icon,
Maria Koulentakia Econcare Lp, Athens, GreeceView further author information
,
Anna Koumarianoub Hematology Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, GreeceView further author information
,
Epaminondas Samadasc Medical Oncology, “METROPOLITAN” Hospital, Piraeus, GreeceView further author information
,
Nikolaos Androulakisd Medical Oncology Unit, Pananio-Venizelio General Hospital of Heraklion, Heraklion, GreeceView further author information
,
Spyridon Xynogalose Medical Oncology, “Metaxas” Cancer Hospital, Piraeus, GreeceView further author information
,
Pavlos Papakotoulasf First Department of Clinical Oncology, Theagenio Hospital, Thessaloniki, GreeceView further author information
,
Ioannis Boukovinasg Oncology Department, Bioclinic of Thessaloniki, Thessaloniki, GreeceView further author information
,
Michalis Karamouzish School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceView further author information
,
John Souglakosi Department of Medical Oncology, University Hospital of Heraklion, Crete, GreeceView further author information
,
Vasiliki Chotzagiannoglouj Servier Hellas Pharmaceuticals Ltd, Athens, GreeceView further author information
,
Alexandra Beletsij Servier Hellas Pharmaceuticals Ltd, Athens, GreeceView further author information
&
Georgia Kourlabaa Econcare Lp, Athens, GreeceView further author information
 show all
Pages 259-269 | Received 18 Dec 2020, Accepted 21 Apr 2021, Published online: 06 May 2021

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

George Gourzoulidis, Oresteia Zisimopoulou, Andrianos Liavas & Charalampos Tzanetakos. (2024) Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece. Expert Review of Pharmacoeconomics & Outcomes Research 24:3, pages 375-385.
Read now
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Hook, Marta Vargas Gomes, Ole Hauch & Ash Bullement. (2023) A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future Oncology 19:9, pages 643-650.
Read now

Articles from other publishers (4)

George Gourzoulidis, Argyro Solakidi, Marina Psarra, Eleni Nikitopoulou & Charalampos Tzanetakos. (2023) Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece. Clinical Drug Investigation 44:1, pages 59-69.
Crossref
George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, Jeffrey Vietri & Charalampos Tzanetakos. (2023) Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece. Frontiers in Public Health 11.
Crossref
Charalampos Tzanetakos & George Gourzoulidis. (2023) Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece. Value in Health Regional Issues 36, pages 18-26.
Crossref
George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos & Georgia Kourlaba. (2022) Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece. Journal of Health Economics and Outcomes Research 9:1, pages 50-57.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.